OPEN END TURBO PUT-OPTIONSSCHEIN MIT SL - GENMAB | Market Closed - Boerse Frankfurt Warrants 03:41:00 2024-07-17 pm EDT | ||
| 7.93 EUR | +1.15% |
|
| Current month | -11.89% | ||
| 1 month | -3.53% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
Latest news about GENMAB A/S
| Date | Price | Change |
|---|---|---|
| 24-07-17 | 7.93 | +1.15% |
| 24-07-16 | 7.84 | -3.21% |
| 24-07-15 | 8.1 | +5.33% |
| 24-07-12 | 7.69 | -6.67% |
| 24-07-11 | 8.24 | -5.83% |
Real-time Boerse Frankfurt Warrants
Last update July 17, 2024 at 03:41 pm EDT
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | GENMAB A/S |
| Issuer | 
Société Générale
|
| WKN | SW884Y |
| ISIN | DE000SW884Y0 |
| Date issued | 2024-04-19 |
| Strike | 2,422 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 5.86 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 9.72 € |
|---|---|
| Lowest since issue | 4.72 € |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
1,829
DKK
Average target price
2,446
DKK
Spread / Average Target
+33.75%
- Stock Market
- Certificates
- Certificat